Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study. (24th May 2022)

• Record Type: Journal Article
• Authors: Landgren, Ola; Weisel, Katja; Rosinol, Laura; Touzeau, Cyrille; Turgut, Mehmet; Hajek, Roman; Mollee, Peter; Kim, Jin Seok; Shu, Natalie; Hu, Xuguang; Li, Chuang; Usmani, Saad Z.
• Is Part Of: British journal of haematology. Volume 198:Number 6(2022)
• Page Start: 988
• Page End: 993
• Publication Date: 2022-05-24
• Subjects: relapsed or refractory multiple myeloma -- proteasome inhibitor -- carfilzomib -- cytogenetics; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.18233
• Languages: English
• ISSNs: 0007-1048

Abstract

Abstract: CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high‐risk and 87% versus 79% in standard‐risk groups. Median progression‐free survival was 11.2 versus 7.4 months in high‐risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard‐risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high‐risk cytogenetics.